Swiss biotech Bioversys AG shares started trading at 36.5 Swiss francs ($40.29) on the SIX Swiss Exchange on Friday, slightly up from the final price for its initial public offering (IPO) of 36 Swiss ...

Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million ...

BioSpace Senior Editor Annalee Armstrong headed to the J.P. Morgan Healthcare Conference with a months-long story idea ...

President Donald Trump's tariff dispute with China, Canada and Mexico over fentanyl smuggling and illegal immigration has led ...

More about Alterity Therapeutics Ltd. Alterity Therapeutics Ltd. operates in the biotechnology industry, focusing on the development of therapies for neurodegenerative diseases. Y ...

"Congratulations to Nancy Etnier, who has been promoted to executive vice president, chief human resources officer," the ...

With 10K genomic data now publicly available, India takes a major leap in genetic research. In today’s 'Knowledge Nugget', ...

In today's rapidly changing business environment, leadership and values are crucial to achieving growth. The stories of visionary leaders have long inspired and shaped industries. In this second ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential.In this article, we are going to take a look at where Legend Biotech Corporation (NASDAQ:LEGN) stands ...

"Building long-term strengths and becoming a high-tech seed service company led by biotechnology is Origin's first consideration," stated Mr. Yan. "We are committed to developing into an ...

Soon after starting a new biotechnology company, David Li realized he needed to rethink his strategy. Li had been conducting the competitive research biotech entrepreneurs typically undertake before ...